Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of its product, Panlong Qiniangao, which is based on a traditional formula and aims to treat knee osteoarthritis [1] Group 1: Product Development - Panlong Qiniangao is an innovative traditional Chinese medicine derived from a proprietary formula by renowned bone injury expert Wang Jiacheng [1] - The product is designed to promote blood circulation, dispel wind and dampness, and reduce swelling and pain, specifically targeting knee osteoarthritis with symptoms of qi stagnation and blood stasis [1] Group 2: Clinical Trial and Regulatory Process - The development process for the drug, including research, clinical trial approval, and production, is lengthy and involves multiple stages [1] - There are uncertainties associated with the clinical trial process that may impact the timeline and outcomes [1]